These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 17202453

  • 1. Dopamine agonists and the risk of cardiac-valve regurgitation.
    Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E.
    N Engl J Med; 2007 Jan 04; 356(1):29-38. PubMed ID: 17202453
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB, Reimold SC, O'Suilleabhain PE.
    Arch Neurol; 2007 Mar 04; 64(3):377-80. PubMed ID: 17353380
    [Abstract] [Full Text] [Related]

  • 6. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E.
    Clin Neurol Neurosurg; 2007 May 04; 109(4):350-3. PubMed ID: 17307289
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
    Oeda T, Masaki M, Yamamoto K, Mizuta E, Kitagawa N, Isono T, Taniguchi S, Doi K, Yaku H, Yutani C, Kawamura T, Kuno S, Sawada H.
    J Neural Transm (Vienna); 2009 Feb 04; 116(2):171-8. PubMed ID: 19082526
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
    Ooba N, Yamaguchi T, Kubota K.
    Drug Saf; 2011 Apr 01; 34(4):329-38. PubMed ID: 21417505
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
    Tran T, Brophy JM, Suissa S, Renoux C.
    CNS Drugs; 2015 Dec 01; 29(12):985-98. PubMed ID: 26585874
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG, Togrol RE.
    Neurology; 2007 Jul 03; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
    Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE.
    Mov Disord; 2004 Jun 03; 19(6):656-62. PubMed ID: 15197703
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.